Granulocyte-Macrophage Colony-Stimulating Factor clinical trials
Counted the way a researcher would: Granulocyte-Macrophage Colony-Stimulating Factor with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses Granulocyte-Macrophage Colony-Stimulating Factor is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Granulocyte-Macrophage Colony-Stimulating Factor studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
117 studies that test it; most in 2004 (12)
| Year | Studies |
|---|---|
| 1998 | 1 |
| 1999 | 3 |
| 2001 | 2 |
| 2002 | 5 |
| 2003 | 4 |
| 2004 | 12 |
| 2005 | 3 |
| 2006 | 8 |
| 2007 | 8 |
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 7 |
| 2012 | 8 |
| 2013 | 6 |
| 2014 | 5 |
| 2015 | 3 |
| 2016 | 3 |
| 2017 | 8 |
| 2018 | 4 |
| 2019 | 3 |
| 2021 | 7 |
| 2022 | 7 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 17 · Other 103
M.D. Anderson Cancer Center (8) · Emory University (5) · Memorial Sloan Kettering Cancer Center (4) · Second Affiliated Hospital of Soochow University (4) · Sellas Life Sciences Group (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · University of Virginia (3) · University Hospital Tuebingen (3)
Often tested with
Tested in the same studies.
Interleukin-2 (10) · Naxitamab (7) · Temozolomide (6) · Cyclophosphamide (5) · Rituximab (5) · Ipilimumab (4) · Granulocyte Colony-Stimulating Factor (4) · Irinotecan (4)
Related medicines
As reviewed, each with the page that says it.
- Sargramostim is a recombinant medicine of it, counted here with related medicines source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4
Studies that test Granulocyte-Macrophage Colony-Stimulating Factor.
- Dec 2026Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk NeuroblastomaPhase 1/2 · Memorial Sloan Kettering Cancer Center
- Jan 2027PRaG Therapy in Combination With Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) (NeoPRAG Study)Phase 1/2 · Second Affiliated Hospital of Soochow University
- Jun 2027Local Spraying of GM-CSF Via Bronchoscopy in the Treatment of Autoimmune Pulmonary Alveolar ProteinosisPhase 2 · Jiuwu Bai
- Jul 2027Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent OsteosarcomaPhase 2 · Memorial Sloan Kettering Cancer Center
Studies
Open first, then newest update. How each study uses Granulocyte-Macrophage Colony-Stimulating Factor is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 120
- Naxitamab Enabled Transplant-Free Study in High-Risk NeuroblastomaRecruitingPhase 2Giselle ShollerNCT07932808Written as Naxitamab and GM-CSF in combination with irinotecan and temozolomideHow we know
- Autologous Stem Cell Transplantation in Patients With Systemic SclerosisRecruitingPhase 2Paul SzabolcsNCT03630211Written as GM-CSFHow we know
- Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCLRecruitingPhase 2The First Affiliated Hospital of Xiamen UniversityNCT07749365Written as hypofractionated radiotherapy plus GM-CSF, pomalidomide and glofitamabHow we know
- NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) TrialRecruitingPhase 2New Approaches to Neuroblastoma Therapy ConsortiumNCT06450041Written as GM-CSFHow we know
- Quadruple Immunotherapy for NeuroblastomaRecruitingPhase 2Hong Kong Children's HospitalNCT05754684Written as Granulocyte-Macrophage Colony-Stimulating FactorHow we know
- Local Spraying of GM-CSF Via Bronchoscopy in the Treatment of Autoimmune Pulmonary Alveolar ProteinosisNot yet recruitingPhase 2Jiuwu BaiNCT06989333Written as GM-CSF (granulocyte-macrophage colony-stimulating factor)How we know
- The Effect of GM-CSF to Preventing Oral Mucositis for Patients With Nasopharyngeal Carcinoma Receiving RadiotherapyRecruitingPhase 2Sun Yat-sen UniversityNCT06472739Written as GM-CSFHow we know
- PRaG Therapy in Combination With Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) (NeoPRAG Study)Not yet recruitingPhase 1/2Second Affiliated Hospital of Soochow UniversityNCT06345599Written as Immunotherapy:Granulocyte macrophage-colony stimulating factor(GM-CSF)、CadumilimabHow we know
- Radiotherapy Combined With PD-1 Inhibitor and GM-CSF for Advanced Recurrent Metastatic Head and Neck TumorsRecruitingPhase 2Xiangpan LiNCT05760196Written as GM-CSFHow we know
- PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors.Not yet recruitingPhase 2Second Affiliated Hospital of Soochow UniversityNCT05530200Written as GM-CSFHow we know
- Metastatic Solid Cancer Clinical TrialCompletedPhase 2ImmunSYS, LLCNCT04739618Written as GM-CSFHow we know
- A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk NeuroblastomaCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT03033303Written as GM-CSFHow we know
- A Study of Sargramostim Plus Pembrolizumab With or Without Pemetrexed in Patients With Advance Non-small Cell Lung Cancer After Completion of ChemoimmunotherapyTerminatedPhase 2Tufts Medical CenterNCT04856176Written as Granulocyte-Macrophage Colony-Stimulating FactorHow we know
- Therapy for Children With Advanced Stage NeuroblastomaCompletedPhase 2St. Jude Children's Research HospitalNCT01857934Written as GM-CSFHow we know
- Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial DiseaseCompletedPhase 2Emory UniversityNCT03304821Written as GM-CSFHow we know
- Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent OsteosarcomaActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT02502786Written as GM-CSFHow we know
- Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and ImiquimodTerminatedPhase 2Beth Israel Deaconess Medical CenterNCT00799110Written as GM-CSFHow we know
- Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone MarrowActive, not recruitingPhase 2Y-mAbs TherapeuticsNCT03363373Written as GM-CSF + NaxitamabHow we know
- Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSFCompletedPhase 1/2Beth Israel Deaconess Medical CenterNCT00458536Written as Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)How we know
- GM-CSF for Reversal of immunopAralysis in pediatriC sEpsis-induced MODS StudyCompletedPhase 4Nationwide Children's HospitalNCT03769844Written as GM-CSFHow we know
See all 120 studies that test Granulocyte-Macrophage Colony-Stimulating Factor →
Given beside what is tested · 56 — Granulocyte-Macrophage Colony-Stimulating Factor is usual care or a partner of the new treatment
- A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer BurdenRecruitingPhase 2University of WashingtonNCT07721259Written as Recombinant Granulocyte-Macrophage Colony-Stimulating FactorHow we know
- A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With NeuroblastomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT04936529Written as GM-CSFHow we know
- Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian CancerNot yet recruitingPhase 2Aston Sci. Inc.NCT05794659Written as rhuGM-CSF(Granulocyte-Macrophage Colony-Stimulating Factor)How we know
- Tebentafusp-tebn With LDT in Metastatic UMRecruitingPhase 1/2Thomas Jefferson UniversityNCT06626516Written as GM-CSF (Sargramostim)How we know
- DC/MM Fusion Vaccine With BCMA CAR-T in R/R MMRecruitingPhase 1David AviganNCT07377435Written as GM-CSFHow we know
- A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple MyelomaRecruitingPhase 1David AviganNCT06799026Written as GM-CSFHow we know
- Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AMLRecruitingPhase 1David AviganNCT07374029Written as GM-CSFHow we know
- Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic MalignanciesRecruitingPhase 1Medical College of WisconsinNCT05544968Written as GM-CSFHow we know
- A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In SituRecruitingPhase 1Mayo ClinicNCT04144023Written as Granulocyte-Macrophage Colony-Stimulating FactorHow we know
- Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid TumorsNot yet recruitingPhase 2Second Affiliated Hospital of Soochow UniversityNCT07327411Written as GM-CSFHow we know
- Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed NeuroblastomaRecruitingPhase 2Sun Yat-sen UniversityNCT06013618Written as GM-CSFHow we know
- Cadonilimab Plus Anlotinib for R/M/P Cervical CancerRecruitingPhase 2Zhongnan HospitalNCT05817214Written as Granulocyte-Macrophage Colony-Stimulating FactorHow we know
- A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung CancerRecruitingPhase 2Second Affiliated Hospital of Soochow UniversityNCT06047860Written as Granulocyte-macrophage colony-stimulating factor subcutaneous injectionHow we know
- Thymalfasin-based PRaG Mode for Advanced Refractory Solid TumorsRecruitingPhase 2Second Affiliated Hospital of Soochow UniversityNCT05790447Written as GM-CSFHow we know
- ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and PembrolizumabNot yet recruitingPhase 2Epitopoietic Research CorporationNCT05366062Written as GM-CSFHow we know
- Study of Chemoimmunotherapy for High-Risk NeuroblastomaActive, not recruitingEarly Phase 1Memorial Sloan Kettering Cancer CenterNCT03189706Written as GM-CSFHow we know
- pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate CancerActive, not recruitingPhase 2University of Wisconsin, MadisonNCT03600350Written as GM-CSFHow we know
- A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including NeuroblastomaCompletedPhase 1/2Eli Lilly and CompanyNCT04238819Written as GM-CSFHow we know
- Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2Active, not recruitingPhase 3Sellas Life Sciences GroupNCT04229979Written as GM-CSFHow we know
- ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma MultiformeActive, not recruitingPhase 2Epitopoietic Research CorporationNCT01903330Written as GM-CSFHow we know
Showing 20 of 56.
As the comparator · 4 — what is tested is compared with Granulocyte-Macrophage Colony-Stimulating Factor
- Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple MyelomaCompletedPhase 2National Cancer Institute (NCI)NCT00006184Written as GMCSF (granulocyte macrophage colony stimulating factor)How we know
- Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in MelanomaCompletedPhase 3BioVex LimitedNCT00769704Written as GM-CSFHow we know
- An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in MelanomaCompletedPhase 3BioVex LimitedNCT01368276Written as Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)How we know
- Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular LymphomaStatus unknownPhase 3Biovest InternationalNCT00091676Written as KLH + GM-CSFHow we know
What changed recently
From the registry's own updates since Oct 20, 2026.
Results posted1
Newly registered1
- Naxitamab Enabled Transplant-Free Study in High-Risk NeuroblastomaNov 12, 2026NCT07932808